Insulin Therapy

An upward trend in nonalcoholic steatohepatitis incidence prompted professional societies to call on clinicians to raise awareness and combine treatment strategies. It was the top story in endocrinology last week.

Adding liraglutide and lifestyle counseling to duodenal mucosal resurfacing eliminated the need for insulin therapy in most patients with type 2 diabetes through 18 months, according to data from a feasibility study.

Adults with type 2 diabetes assigned an investigational once-weekly insulin therapy experienced a decrease in HbA1c similar to that seen with daily insulin glargine, according to findings from a phase 2 randomized controlled trial.

Clinicians must adapt protocols for optimal inpatient glycemic management during the COVID-19 pandemic as part of an effort to incorporate new therapies, limit direct patient contact and minimize infection risk, researchers wrote.

The FDA on Friday issued a complete response letter for a supplemental new drug application for a 2.5 mg dose of the SGLT2 inhibitor empagliflozin as an adjunct to insulin for adults with type 1 diabetes, according to a press release from Boehringer Ingelheim and Eli Lilly.

Chinese adults with type 1 diabetes can avoid insulin-related weight gain and use less insulin by adding metformin to treatment regimens, according to findings published in the Journal of Diabetes.

Adults with type 2 diabetes who decide not to take insulin are less likely to reduce their HbA1c below 7% over 12 months than those who initiate insulin when recommended, according to findings published in Diabetic Medicine.

Adults with type 2 diabetes who lost enough weight to enter diabetes remission were also able to achieve normal beta-cell function. It was the top story in endocrinology last week.

An investigational, once-daily pill added to optimized insulin therapy was shown to reduce HbA1c among adults with type 1 diabetes during a 12-week trial when compared with placebo plus insulin, according to a press release from vTv Therapeutics.

An analysis of two real-world studies comparing standard of care basal insulin therapy with insulin glargine 300 U/mL suggests that more patient and provider support are needed regarding insulin dosing and titration, according to findings published in Current Medical Research and Opinion.